| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6635280 | SANTARUS INC | Extending the duration of drug release within the stomach during the fed mode |
Sep, 2016
(7 years ago) | |
| US6340475 | SANTARUS INC | Extending the duration of drug release within the stomach during the fed mode |
Sep, 2016
(7 years ago) | |
| US6488962 | SANTARUS INC | Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms |
Jun, 2020
(3 years ago) | |
| US6723340 | SANTARUS INC | Optimal polymer mixtures for gastric retentive tablets |
Oct, 2021
(2 years ago) | |
| US7780987 | SANTARUS INC | Controlled release dosage forms |
Mar, 2025
(10 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8323692 | SANTARUS INC | Controlled release dosage forms |
Mar, 2023
(1 year, 28 days ago) | |
Glumetza is owned by Santarus Inc.
Glumetza contains Metformin Hydrochloride.
Glumetza has a total of 6 drug patents out of which 5 drug patents have expired.
Expired drug patents of Glumetza are:
- US8323692
- US6635280
- US6340475
- US6488962
- US6723340
Glumetza was authorised for market use on 03 June, 2005.
Glumetza is available in tablet, extended release;oral dosage forms.
Glumetza can be used as indication of type ii diabetes.
The generics of Glumetza are possible to be released after 23 March, 2025.
Drugs and Companies using METFORMIN HYDROCHLORIDE ingredient
Market Authorisation Date: 03 June, 2005
Treatment: Indication of type ii diabetes
Dosage: TABLET, EXTENDED RELEASE;ORAL
How can I launch a generic of GLUMETZA before it's drug patent expiration?
More Information on Dosage
GLUMETZA family patents
